Our Technology
PATENT PROTECTED HYDROGEL
Our platform technology consists of mainly two materials which have the following properties:
Shear Thinning
Inverse Thermal Gelling
Our hydrogel provides a sustained therapeutic release which out-competes other available technologies.
OUR SERVICES
About Us
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.
Based on the research of world-renowned biomaterials scientist, Dr. Molly Shoichet, AmacaThera is commercializing combination products at the interface of biomaterials and pharmaceuticals.
We have developed a platform technology which addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas.
Currently, we have developed a combination product for post-operative pain, which is our company's lead project.
Improving the lives of patients by providing sustained therapeutic release.
Need more details? Contact us
We are here to assist. Contact us by phone, email or via our social media channels.
Meet The Team
Management Team
Our
Achievements
ACADEMIC RESEARCH PAPERS
27
Papers published on our technology alone
THIRD PARTY VALIDATION
02
Papers published by independent groups
AMOUNT OF MONEY RAISED
1.2M
Non-dilutive funding
OUR AFFILIATIONS
